A new CEO, a $5 billion share-repurchase program, and a handful of promising new drugs make Pfizer shares look cheap even after today's runup, according to Morningstar's Damien Conover.
A new ROIC-focused process for compound development plus the value of Pfizer's other businesses add up to a fair value well in excess of $14, says RS Investments manager Joe Wolf.
Morningstar markets editor Jeremy Glaser looks at if the congressional supercommittee, Coach, Pfizer, Comcast, and Kraft can deliver the goods.
Pharmaceutical firms' adept handling of patent expirations has boosted investors' opinions of the sector, says Morningstar's Damien Conover.
Good day everyone, and welcome to today's Bristol-Myers Squibb Fourth Quarter Earnings 2010 Earnings Release Conference Call. Today's call is being recorded.
Good day, and welcome to today's Third Quarter 2012 Earnings Release Conference Call. As a reminder, this call is being recorded.
Good day and welcome to today's Second Quarter 2011 Earnings Conference Call. This call is being recorded.
©2012 Morningstar Advisor. All right reserved.